EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020–2024)

S Kalantri, B Kelley, J Q Freeman, T O Akhiwu, R Redman

Clinical Oncology · 2026-09 · 57 · 104221

DOI: 10.1016/j.clon.2026.104221 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Oncology, 2026-09. Verfasst von S Kalantri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA. Electronic address: shreyas.kalantri@l…. Hauptthemen laut MEDLINE: Quality of Life, Gastrointestinal Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Advanced gastrointestinal (GI) cancers negatively impact patients' quality of life (QoL). Incorporating QoL endpoints is essential for holistic therapeutic assessment. This systematic review investigated QoL inclusion in advanced GI cancer phase III clinical trials and its associated factors. METHODS: A PubMed search identified 3795 articles published between January 2020 and December 2024. After applying inclusion and exclusion criteria, 80 trials evaluating novel agents or dosing regimens were analyzed. Multivariable logistic regression was performed. RESULTS: Of the 80 trials, 60% included QoL as an endpoint, predominantly as secondary (68.7%) or exploratory (31.3%) endpoints; none incorporated QoL as a primary endpoint. Single-country trials had lower QoL inclusion than multi-country trials (41.9% vs 81.1%; aOR, 0.15, 95% CI, 0.04-0.53; P = 0.003). Studies in journals with impact factors >10 showed greater QoL inclusion (65.4%) compared to those with impact factors

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeGastrointestinal NeoplasmsHumansClinical Trials, Phase III as TopicClinical Trials as Topic

Stichwörter der Autor:innen

Advanced gastrointestinal cancerspatient-reported outcomesphase III trialsquality of lifesystematic review

Autor:innen und Institutionen

  • Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA. Electronic address: shreyas.kalantri@louisville.edu.
  • Department of Internal Medicine, University of Louisville, Louisville, USA.
  • Department of Public Health Sciences, University of Chicago, Chicago, IL, USA; Cancer Prevention and Control Research Program, UChicago Medicine Comprehensive Cancer Center, Chicago, IL, USA; Center for Health and the S…
  • Department of Medicine, MedStar Health Union Memorial Hospital, Baltimore, MD, USA.
  • Division of Medical Oncology & Hematology, Brown Cancer Center, University of Louisville, Louisville, KY, USA.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Kalantri, S., Kelley, B., Freeman, J. Q., Akhiwu, T. O., & Redman, R. (2026). Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020–2024). Clinical Oncology, 57, 104221. https://doi.org/10.1016/j.clon.2026.104221

Vancouver

Kalantri S, Kelley B, Freeman JQ, Akhiwu TO, Redman R. Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020–2024). Clinical Oncology. 2026;57:104221. doi:10.1016/j.clon.2026.104221

BibTeX
@article{Kalantri2026,
  author = {Kalantri, S and Kelley, B and Freeman, J Q and Akhiwu, T O and Redman, R},
  title = {Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020–2024)},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {57},
  pages = {104221},
  doi = {10.1016/j.clon.2026.104221}
}
Kostenlos starten →